this presentation is based on company profile.

2. •Dr. Reddy's Laboratories

5. Dr. Reddy was an Indian entrepreneur in the
pharmaceutical industry, the founder-chairman of Dr.
Reddy's Laboratories, which he established in 1984, and
chairman of Dr Reddy's Foundation (DRF), the corporate
social responsibility arm of the group, established 1996.The
Government of India, honoured him with the Padma Shri in
2001 and followed it up, later, with the Padmabhushan, for
his contribution to the Indian Pharmaceutical industry. He
was a member of the Indian Prime Minister's Council on
Trade and Industry.

6. • Reddy after graduating from the local high school,
went on to get his first Bachelor of science degree
from Andhra Christian College or A.C. College at
Guntur in 1958. Thereafter he, did his BSc-Tech in
Pharmaceuticals and Fine chemicals from UDCT,
Mumbai followed by a PhD in chemical
engineering from the National Chemical
Laboratory, Pune in 1969.

8. COMPANY BACKGROUND
• Dr.Reddy’s Laboratories Ltd founded in 1984 by
Dr k.Angi Reddy has become India’s second
biggest pharmaceutical company and its
headquartered is in Hyderabad.
• It produces and sells active pharmaceutical
ingredients , finished dosages and biologics.
• It manufactures ulcer medicines, antibiotics, pain
relievers, antidepressants and cardiovascular
drugs.

9. • ON 11April 2001, Dr Reddy’s became the first
pharmaceutical company from Asia Pacific to be
listed on Newyork stock exchange.
• The company carries out research and
development in diabetes, cancer, cardiovascular
diseases and bacterial infections.
• The company has over 120 medications and 60
active pharmaceutical ingredients for drug
manufacture.

10. • Dr Reddy’s market its product in approximately
100 countries , focusing on Europe, India,US and
Russia.
• The company employed over 8255 personnel,
• In 1997 it became the first Indian company to
out-license an original molecule (DRF 2593).
• Its revenue for 2006 - 2007 amounted to $ 1.5
billion, an increase of 24.3% of the previous year
. Its net income amounts to $ 216 million.

11. Company history
• Dr. Reddy's originally launched in 1984 producing
active pharmaceutical ingredients. In 1986,
Reddy's started operations on branded
formulations. Within a year Reddy's had launched
Norilet, the company's first recognized brand in
India. Soon, Dr. Reddy's obtained another success
with Omez, its branded omeprazole – ulcer and
reflux oesophagitis medication – launched at half
the price of other brands on the Indian market at
that time.

12. • Within a year, Reddy's became the first Indian
company to export the active ingredients for
pharmaceuticals to Europe. In 1987, Reddy's
started to transform itself from a supplier of
pharmaceutical ingredients to other
manufacturers into a manufacturer of
pharmaceutical products.

13. Dr.Reddy's began as a supplier to Indian drug manufacturers,
but it soon started exporting to other less-regulated markets
that had the advantage of not having to spend time and
money on a manufacturing plant that would gain approval
from a drug licensing body such as the U.S. Food and Drug
Administration (FDA). By the early 1990s, the expanded scale
and profitability from these unregulated markets enabled the
company to begin focusing on getting approval from drug
regulators for their formulations and bulk drug manufacturing
plants in more-developed economies.

14. Baceuticalngredients in India and seven FDA-inspected and ISO 9001
(quality) and ISO 14001 (environmental management) certified plants
m In 2010, the family-controlled Dr Reddy's denied
that it was in talks to sell its generics business in
India to US pharmaceutical giant Pfizer, which had
been suing the company for alleged patent
infringement after Dr Reddy's announced that it
intended to produce a generic version of
atorvastatin, marketed by Pfizer as Lipitor, an anti-
cholesterol medication. Reddy's was already linked
to UK pharmaceuticals multinational Glaxo
Smithkline.

15. In other European countries
• Apart from subsidiaries in Germany and UK ,
Dr.Reddy’s has agreements in following
European countries.
• DENMARK
• IRELAND
• NETHERLANDS

16. Factors for success
• Controlling the entire value chain
• Implementations of efficient new product
development processes
• High standard of corporate governance

17. Implementations of efficient new
product development processes
• Targeting the streamlining of new product
development process, Dr. Reddy’s implemented
project ‘racha’ using Microsoft accelerator for six
sigma. This is helping the company in taking key
decisions to launch the right products in the
market at the appropriate time.

18. High standard of corporate
governance
• Dr.Reddy’s adherence to high standard
of corporate governance and ethical
business practices has been a key factor
to its success. The mutual trust has
ensured greater success for the company.

19. Future plans
• Having acquired Betapharm, one of the fastest
growing generic companies in Germany over the
past 5 years, Dr.Reddy’s aims at leveraging this
strategic investment to evolve into a mid-sized
global pharmaceutical company. Dr.Reddy’s aims
to increase its revenue substantially and
improve its operating margin.

20. Dr. Reddy's starts clinical trials for CD
TNN Feb 8, 2005, 12.43am IST
• HYDERABAD: Dr Reddy's Laboratories has initiated
Phase I clinical trials for its cardiovascular drug
candidate RUS 3108. They are being conducted in
Belfast, Ireland. The phase I trials will explore the
safety and pharmacokinetic profiles of this drug
candidate in humans.
• This is the first time the company is testing a drug in
Europe. RUS 3108 is being developed for the
treatment of atherosclerosis, the major cause of heart
attacks and strokes. There are currently no drugs that
directly treat atherosclerosis.

21. • According to a company statement, the drug
represents a new approach to the treatment of
atherosclerosis. The RUS 3108 works by
affecting multiple pathways involved in the
disease like inflammation, proliferation and
thrombosis by inducing a protein called
perlecan.
• Company scientists have determined that
regulating the expression of perlecan can
provide direct protection against the disease.

22. • Uday Saxena, chief scientific officer of Dr Reddy's
said, "RUS 3108 represents a unique approach
for treatment of cardiovascular diseases, a
growing unmet medical need worldwide."
• Dr Reddy's conducts its drug discovery research
in Hyderabad and Atlanta and has discovery
programmes in the areas of diabetes,
cardiovascular, anti-infectives, inflammation and
cancer. The company currently has six new
chemical entities at various stages of clinical
development

23. Clinical Research Associate Jobs in Dr.
Reddy's
Internal : QA, Pharmacovigilence,
Medical writing, Medico Marketing, Data Management,,
Quality Check, Medical, Clinical Research Associate,
Regulatory, Formulation Development and Medico-
marketing teams
External : Site Investigators, CRO

24. job as QUALITY ASSURANCE
• EXPERIENCE: 4-8 years
• EDUCATION: M.SC./B.SC
Experience in handling IPQA/ Validation and
training activities in quality assurance
department of a pharnaceutical plant(OSD,
Ointment/ Injectables).

25.  Our Purpose
WE ACCELERATE ACCESS TO AFFORDABLE AND
INNOVATIVE MEDICINES

27. TOP RANKING IN INDIA
• A vast range of pharmaceutical products are offered
by Dr. Reddy's Labs. It has 60 APIs and 190
medications to treat various kinds of ailments. It is
now India's third largest pharmaceutical company in
terms of market capitalisation, which was valued at Rs.
56,638.13 crore on 15 June 2015. Its products and
services may be categorised as below:
• Generic Formulations
• Active Ingredients
• Pharmaceutical Services
• Biosimilars
• Propriety Product

28. Laboratories Aims
at making the lives of the individuals healthier and happier.
This company is one of the most popular pharmaceutical
companies with base in more than 100 countries. The
medicines of Dr. Reddy's Laboratories Limited are easily
available all across the globe.
Dr. Reddy's Pharmaceutical Company is very much
customer friendly. It takes care of the fact that maximum
people get benefited by the products of this
pharmaceutical company. It commercialized various
treatments so as to provide high tech treatment to the
masses. It tries to meet the medical needs of the people.

29. Though Dr. Reddy's Laboratories is located in various parts
of the world, it has its headquarters in India. This global
pharmaceutical company can be found over 100 countries.
The subsidiaries of this company are found at various
countries like US, Germany, UK, Russia and Brazil. 16
countries have the representative offices of Dr. Reddy's
Laboratories Limited. 21 countries have third party
distribution. It is one of the prestigious companies to be
listed in NYSE.

30. It is because of the best quality products and wide reach of
its medicines that it gives a tough competition to other
pharmaceutical companies. It has already left a mark in the
global pharmaceutical market.
Dr. Reddy's Pharmaceutical Company has some set values
that make it stand out among all pharmaceutical
companies. These include:
 Quality
 Harmony and social responsibility
 Respect for the individual
 Collaboration and team work
 Innovation and continuous learning

31. CONTACT
• Contact Details of Dr. Reddy's Laboratories
• Corporate Office
• Dr. Reddy's Laboratories Ltd.
• Greenlands, Ameerpet,
• Hyderabad 500 016, INDIA
• Tel: +91-40-23731946-50
• Fax: +91-40-23731955
• Visit: www.drreddys.com

32. Dr Reddy's Zoloft generic case
dismissed in USA
• India-headquartered Dr Reddy's Laboratories says that a
District Court for the state of New Jersey, USA, has declined
to hear the company's suit seeking a judgement that would
allow it to market a generic version of Pfizer's
antidepressant Zoloft (sertraline).
• Dr Reddy's filed an application for approval of the
compound with the US Food and Drug Administration in
25mg, 50mg and 100mg tablet forms, and was seeking a
decision on whether its generic version infringed Pfizer's
branded product after the latter firm failed to lodge a suit
against it within the 45-day period granted under current
regulations.

33. • The case was dismissed on the basis that Pfizer
required more time to examine if an
infringement had taken place. Dr Reddy's
responded by saying that it intended to provide
Pfizer with whatever information it needed and,
if necessary, renew its suit thereafter.

34. Dr. Reddy’s statement on the receipt of Warning Letter
from US FDA
Dr. Reddy’s Laboratories ( BSE: 500124 / NSE: DRREDDY /
NYSE: RDY ) today issued a statement acknowledging that it
has received a warning letter issued by the US FDA dated
November 05, 2015 relating to its API manufacturing
facilities at Srikakulam, Andhra Pradesh and Miryalaguda,
Telangana, as well as Oncology Formulation manufacturing
facility at duvvada, Visakhapatnam, Andhra Pradesh. This
action follows the earlier inspections of these sites by the
agency in November 2014, January 2015 and February 2015
respectively.

35. • Dr. Reddy’s CEO, G V Prasad commented “We take
quality and compliance matters seriously and stand by
our commitment to fully comply with the cGMP quality
standards across all of our facilities We will respond
comprehensive plan to address these observations
within the stipulated time-frame of 15 days. We will
continue to actively engage with the agency to resolve
these issues and we have also embarked on an initiative
to revamp our quality systems and processes, as an
organization - wide priority.

36.  Employee Reviews
 “ Good Place to Work ”
 “Good company, growth depends on department head ”
 “Great Place to learn the business nuances of Pharma at the
start of career.... ”
Amazing opportunities but highly challenging ”
“Quality assurance ”